UB Paderborn / Katalog / Suche / in CDI

1 – 16 von 16

Sortiert nach

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival

NPJ breast cancer, 2023-07, Vol.9 (1), p.61-61, Article 61

2023

Volltextzugriff (PDF)

Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial

Breast cancer research and treatment, 2024-05, Vol.205 (1), p.87-95

2024

Volltextzugriff (PDF)

Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age

Breast cancer research and treatment, 2015-11, Vol.154 (1), p.171-180

2015

Volltextzugriff (PDF)

The effect of (neo)adjuvant chemotherapy on long‐term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study

Cancer, 2024-03, Vol.130 (6), p.927-935

2024

Volltextzugriff (PDF)

Denosumab in breast cancer treatment

European journal of pharmacology, 2013-10, Vol.717 (1-3), p.12-19

2013

Volltextzugriff (PDF)

Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature

Cancer treatment reviews, 2015-02, Vol.41 (2), p.187-196

2015

Volltextzugriff (PDF)

The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction

International journal of cancer, 2022-08, Vol.151 (4), p.616-622

2022

Volltextzugriff (PDF)

First‐Line Palliative HER2‐Targeted Therapy in HER2‐Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab‐Based Therapy

The oncologist (Dayton, Ohio), 2017-08, Vol.22 (8), p.901-909

2017

Volltextzugriff (PDF)

Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies

International journal of hyperthermia, 2018-06, Vol.34 (4), p.407-414

2018

Volltextzugriff (PDF)

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

Breast cancer research and treatment, 2016-04, Vol.156 (3), p.557-566

2016

Volltextzugriff (PDF)

Development and validation of an UPLC–MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair

Journal of pharmaceutical and biomedical analysis, 2015-10, Vol.114, p.416-425

2015

Volltextzugriff (PDF)

Development of a Clinical Prediction Model for 1-Year Mortality in Patients With Advanced Cancer

JAMA network open, 2022-11, Vol.5 (11), p.e2244350-e2244350

2022

Volltextzugriff (PDF)

Neutrophil-guided dosing of anthracycline–cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study

Medical oncology (Northwood, London, England), 2015-04, Vol.32 (4), p.113, Article 113

2015

Volltextzugriff (PDF)

Abstract PS13-21: Cardiac function in patients receiving trastuzumab for HER2+ metastatic breast cancer with left ventricular ejection fraction<50% at baseline

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS13-21-PS13-21

2021

Volltextzugriff (PDF)

Abstract P4-15-12: Results from a randomized phase II study of the Dutch Breast Cancer Research Group (BOOG 2008-03): Concomitant trastuzumab, bevacizumab and paclitaxel (HAT) versus trastuzumab and bevacizumab, followed by trastuzumab, bevacizumab and paclitaxel (HA-HAT) a

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P4-P4-15-12

2015

Volltextzugriff (PDF)

1 – 16 von 16

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(16)

Sprache

Englisch
(16)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Oncology
(12)
Humans
(11)
Breast Cancer
(10)
Female
(10)
Aged
(8)
Middle Aged
(8)
Adult
(7)
Breast Neoplasms - Pathology
(7)
Breast Neoplasms - Drug Therapy
(6)
Cancer Therapies
(4)
Chemotherapy
(4)
Medicine
(4)
Medicine & Public Health
(4)
Metastasis
(4)
Mutation
(4)
Trastuzumab
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Brca Mutation
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival

Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial

Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age

The effect of (neo)adjuvant chemotherapy on long‐term survival outcomes in patients with invasive lobular breast cancer treated with endocrine therapy: A retrospective cohort study

Denosumab in breast cancer treatment

Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: A critical review of the literature

The effect of trastuzumab on cardiac function in patients with HER2‐positive metastatic breast cancer and reduced baseline left ventricular ejection fraction

First‐Line Palliative HER2‐Targeted Therapy in HER2‐Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab‐Based Therapy

Heat-induced BRCA2 degradation in human tumours provides rationale for hyperthermia-PARP-inhibitor combination therapies

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer

Development and validation of an UPLC–MS/MS method for the quantification of tamoxifen and its main metabolites in human scalp hair

Development of a Clinical Prediction Model for 1-Year Mortality in Patients With Advanced Cancer

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy‐free approach in HER2‐positive metastatic breast cancer: The HAT study (BOOG 2008‐2003), a Dutch Breast Cancer Research Group trial

Neutrophil-guided dosing of anthracycline–cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study

Abstract PS13-21: Cardiac function in patients receiving trastuzumab for HER2+ metastatic breast cancer with left ventricular ejection fraction<50% at baseline

Abstract P4-15-12: Results from a randomized phase II study of the Dutch Breast Cancer Research Group (BOOG 2008-03): Concomitant trastuzumab, bevacizumab and paclitaxel (HAT) versus trastuzumab and bevacizumab, followed by trastuzumab, bevacizumab and paclitaxel (HA-HAT) a

Suchergebnisse filtern